ABUS vs. IBRX, MLTX, BEAM, VCEL, CNTA, DNLI, KYMR, MIRM, GMTX, and BLTE
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include ImmunityBio (IBRX), MoonLake Immunotherapeutics (MLTX), Beam Therapeutics (BEAM), Vericel (VCEL), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), Kymera Therapeutics (KYMR), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.
Arbutus Biopharma vs.
Arbutus Biopharma (NASDAQ:ABUS) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
Arbutus Biopharma has higher earnings, but lower revenue than ImmunityBio. Arbutus Biopharma is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma has a net margin of -1,137.65% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Arbutus Biopharma's return on equity.
43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 4.0% of Arbutus Biopharma shares are owned by insiders. Comparatively, 83.4% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Arbutus Biopharma currently has a consensus target price of $5.50, suggesting a potential upside of 58.27%. ImmunityBio has a consensus target price of $12.19, suggesting a potential upside of 316.67%. Given ImmunityBio's higher possible upside, analysts plainly believe ImmunityBio is more favorable than Arbutus Biopharma.
Arbutus Biopharma has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
Arbutus Biopharma received 420 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 70.66% of users gave Arbutus Biopharma an outperform vote while only 43.24% of users gave ImmunityBio an outperform vote.
In the previous week, Arbutus Biopharma had 12 more articles in the media than ImmunityBio. MarketBeat recorded 21 mentions for Arbutus Biopharma and 9 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.67 beat Arbutus Biopharma's score of 0.47 indicating that ImmunityBio is being referred to more favorably in the news media.
Summary
Arbutus Biopharma beats ImmunityBio on 10 of the 18 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:ABUS) was last updated on 3/31/2025 by MarketBeat.com Staff
